TOI Quote, Financials, Valuation and Earnings

Encompass Health Corp. has a net margin of -4.53% compared to The Oncology Institute, Inc.'s net margin of 13.07%. The Oncology Institute, Inc.'s return on equity of -9486.64% beat Encompass Health Corp.'s return on equity of 24.73%.

The Oncology Institute, Inc. has a consensus price target of $7.00, signalling upside risk potential of 124.36%. On the other hand Encompass Health Corp. has an analysts' consensus of $142.73 which suggests that it could grow by 46.55%. Given that The Oncology Institute, Inc. has higher upside potential than Encompass Health Corp., analysts believe The Oncology Institute, Inc. is more attractive than Encompass Health Corp..

The Oncology Institute, Inc. has a beta of 0.171, which suggesting that the stock is 82.894% less volatile than S&P 500. In comparison Encompass Health Corp. has a beta of 0.768, suggesting its less volatile than the S&P 500 by 23.159%.

The Oncology Institute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health Corp. offers a yield of 0.76% to investors and pays a quarterly dividend of $0.19 per share. The Oncology Institute, Inc. pays -- of its earnings as a dividend. Encompass Health Corp. pays out 13% of its earnings as a dividend. Encompass Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

The Oncology Institute, Inc. quarterly revenues are $142M, which are smaller than Encompass Health Corp. quarterly revenues of $1.5B. The Oncology Institute, Inc.'s net income of -$6.4M is lower than Encompass Health Corp.'s net income of $201.9M. Notably, The Oncology Institute, Inc.'s price-to-earnings ratio is -- while Encompass Health Corp.'s PE ratio is 17.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute, Inc. is 0.57x versus 1.68x for Encompass Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Elite Health Systems, Inc. has a net margin of -4.53% compared to The Oncology Institute, Inc.'s net margin of --. The Oncology Institute, Inc.'s return on equity of -9486.64% beat Elite Health Systems, Inc.'s return on equity of -72.99%.

The Oncology Institute, Inc. has a consensus price target of $7.00, signalling upside risk potential of 124.36%. On the other hand Elite Health Systems, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that The Oncology Institute, Inc. has higher upside potential than Elite Health Systems, Inc., analysts believe The Oncology Institute, Inc. is more attractive than Elite Health Systems, Inc..

The Oncology Institute, Inc. has a beta of 0.171, which suggesting that the stock is 82.894% less volatile than S&P 500. In comparison Elite Health Systems, Inc. has a beta of 0.545, suggesting its less volatile than the S&P 500 by 45.523%.

The Oncology Institute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elite Health Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Oncology Institute, Inc. pays -- of its earnings as a dividend. Elite Health Systems, Inc. pays out -- of its earnings as a dividend.

The Oncology Institute, Inc. quarterly revenues are $142M, which are larger than Elite Health Systems, Inc. quarterly revenues of --. The Oncology Institute, Inc.'s net income of -$6.4M is lower than Elite Health Systems, Inc.'s net income of -$1.2M. Notably, The Oncology Institute, Inc.'s price-to-earnings ratio is -- while Elite Health Systems, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute, Inc. is 0.57x versus 7.08x for Elite Health Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pediatrix Medical Group, Inc. has a net margin of -4.53% compared to The Oncology Institute, Inc.'s net margin of 6.82%. The Oncology Institute, Inc.'s return on equity of -9486.64% beat Pediatrix Medical Group, Inc.'s return on equity of 19.95%.

The Oncology Institute, Inc. has a consensus price target of $7.00, signalling upside risk potential of 124.36%. On the other hand Pediatrix Medical Group, Inc. has an analysts' consensus of $21.33 which suggests that it could grow by 0.72%. Given that The Oncology Institute, Inc. has higher upside potential than Pediatrix Medical Group, Inc., analysts believe The Oncology Institute, Inc. is more attractive than Pediatrix Medical Group, Inc..

The Oncology Institute, Inc. has a beta of 0.171, which suggesting that the stock is 82.894% less volatile than S&P 500. In comparison Pediatrix Medical Group, Inc. has a beta of 0.719, suggesting its less volatile than the S&P 500 by 28.12%.

The Oncology Institute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pediatrix Medical Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Oncology Institute, Inc. pays -- of its earnings as a dividend. Pediatrix Medical Group, Inc. pays out -- of its earnings as a dividend.

The Oncology Institute, Inc. quarterly revenues are $142M, which are smaller than Pediatrix Medical Group, Inc. quarterly revenues of $493.8M. The Oncology Institute, Inc.'s net income of -$6.4M is lower than Pediatrix Medical Group, Inc.'s net income of $33.7M. Notably, The Oncology Institute, Inc.'s price-to-earnings ratio is -- while Pediatrix Medical Group, Inc.'s PE ratio is 11.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute, Inc. is 0.57x versus 0.97x for Pediatrix Medical Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

U.S. Physical Therapy, Inc. has a net margin of -4.53% compared to The Oncology Institute, Inc.'s net margin of 6.45%. The Oncology Institute, Inc.'s return on equity of -9486.64% beat U.S. Physical Therapy, Inc.'s return on equity of 8.4%.

The Oncology Institute, Inc. has a consensus price target of $7.00, signalling upside risk potential of 124.36%. On the other hand U.S. Physical Therapy, Inc. has an analysts' consensus of $104.00 which suggests that it could grow by 41.04%. Given that The Oncology Institute, Inc. has higher upside potential than U.S. Physical Therapy, Inc., analysts believe The Oncology Institute, Inc. is more attractive than U.S. Physical Therapy, Inc..

The Oncology Institute, Inc. has a beta of 0.171, which suggesting that the stock is 82.894% less volatile than S&P 500. In comparison U.S. Physical Therapy, Inc. has a beta of 1.351, suggesting its more volatile than the S&P 500 by 35.149%.

The Oncology Institute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. U.S. Physical Therapy, Inc. offers a yield of 2.48% to investors and pays a quarterly dividend of $0.46 per share. The Oncology Institute, Inc. pays -- of its earnings as a dividend. U.S. Physical Therapy, Inc. pays out 126.62% of its earnings as a dividend.

The Oncology Institute, Inc. quarterly revenues are $142M, which are smaller than U.S. Physical Therapy, Inc. quarterly revenues of $202.7M. The Oncology Institute, Inc.'s net income of -$6.4M is lower than U.S. Physical Therapy, Inc.'s net income of $13.1M. Notably, The Oncology Institute, Inc.'s price-to-earnings ratio is -- while U.S. Physical Therapy, Inc.'s PE ratio is 51.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute, Inc. is 0.57x versus 1.42x for U.S. Physical Therapy, Inc.. Usually stocks with elevated PS ratios are considered overvalued.